A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.

Autor:	van Tol S; Laboratory of Virology., Fletcher P; Laboratory of Virology., Feldmann F; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Mukesh RK; Laboratory of Virology., Port JR; Laboratory of Virology., Gallogly S; Laboratory of Virology., Schulz JE; Laboratory of Virology., Rhoderick JF; Laboratory of Virology., Makinson R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom., Carmody A; Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Myers L; Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Lovaglio J; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Smith BJ; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Okumura A; Laboratory of Virology., Shaia C; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Saturday G; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Marzi A; Laboratory of Virology., Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom., Munster VJ; Laboratory of Virology., van Doremalen N; Laboratory of Virology.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Nov 15; Vol. 230 (5), pp. 1083-1092.
DOI:	10.1093/infdis/jiae056
Abstrakt:	The most recent Sudan virus (SUDV) outbreak in Uganda was first detected in September 2022 and resulted in 164 laboratory-confirmed cases and 77 deaths. There are no approved vaccines against SUDV. Here, we investigated the protective efficacy of ChAdOx1-biEBOV in cynomolgus macaques using a prime or a prime-boost regimen. ChAdOx1-biEBOV is a replication-deficient simian adenovirus vector encoding SUDV and Ebola virus (EBOV) glycoproteins (GPs). Intramuscular vaccination induced SUDV and EBOV GP-specific immunoglobulin G responses and neutralizing antibodies. Upon challenge with SUDV, vaccinated animals showed signs of disease like those observed in control animals, and no differences in survival outcomes were measured among all 3 groups. Viral load in blood samples and in tissue samples obtained after necropsy were not significantly different between groups. Overall, this study highlights the importance of evaluating vaccines in multiple animal models and demonstrates the importance of understanding protective efficacy in both animal models and human hosts. Competing Interests: Potential conflicts of interest. T. L. reports consulting fees from Vaccitech on an unrelated project, has received honorarium from Seqirus on an unrelated project, and is named as an inventor on a patent application for a vaccine against SARS-CoV-2. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu